Eli Lilly reported Phase 3 results showing its triple‑agonist retatrutide produced a mean 28.7% body‑weight reduction at 68 weeks in the trial population. The data, from the program’s high‑dose arm, represent one of the largest average reductions seen in a late‑stage obesity study to date. Trial readouts also flagged elevated discontinuation and side‑effect rates, prompting analysts to note a trade‑off between potency and tolerability. The result is already reshaping competitor expectations for clinical efficacy benchmarks in obesity drug development.